Pharmaceuticals

Amylyx Pharmaceuticals

Amylyx Pharmaceuticals released FY2026 Q1 earnings on May 7 Pre-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3733 (forecast USD -0.3616)

Amylyx reports Q1 net loss increase with rising R&D expenses

Amylyx Pharmaceuticals to Release FY2026 Q1 Earnings on May 7 Pre-Market EST, Forecast Revenue USD 0, EPS USD -0.3557

Amylyx Pharmaceuticals released FY2025 Q4 earnings on March 3 Pre-Market (EST), actual EPS USD -0.3004 (forecast USD -0.3377)

Amylyx Pharmaceuticals released FY2025 earnings on March 3 Pre-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD 0 (forecast USD -1.5277)

Amylyx Pharmaceuticals to Release FY2025 Q4 Earnings on March 3, Pre-Market EST, Forecast EPS USD -0.3375

Amylyx Pharmaceuticals Presents Early Phase I Clinical Trial Results of ALS Drug AMX0114 at International Symposium

Amylyx Pharmaceuticals Inc Announces Safety and Tolerability Data for AMX0114 in ALS

Amylyx Pharmaceuticals released FY2025 9 Months earnings on November 6, Pre-Market (EST), actual revenue USD 0, actual EPS USD -1.2539

Amylyx Pharmaceuticals released FY2025 Q3 earnings on November 6 Pre-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3684 (forecast USD -0.4437)

Amylyx Pharmaceuticals Inc. Successfully Raised Funds Through IPO Extending Cash Flow

Amylyx Pharmaceuticals Reports Lower-than-Expected Third-Quarter Earnings

Amylyx Pharmaceuticals to Release FY2025 Q3 Earnings on November 6, Pre-Market EST, Forecast EPS: USD -0.4437

Tim Anderson gives Amylyx Pharmaceuticals a buy rating

Amylyx Pharmaceuticals insider selling company stocks

Chief Legal Officer of Amylex Pharmaceuticals Sold Company Common Stock

Amylyx Pharmaceuticals Inc. Voluntarily Withdraws Approval Request for RELYVRIO for ALS Treatment

Amylyx Pharmaceuticals Terminates AMX0035 Trial in PSP and Focuses on Other Drug Projects

Amylyx Pharmaceuticals released FY2025 Semi-Annual earnings on August 7 Pre-Market EST, actual revenue USD 0, actual EPS USD -0.8847

Amylyx Pharmaceuticals released FY2025 Q2 earnings on August 7 Pre-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4649 (forecast USD -0.45)

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Silexion Therapeutics

Micware

GCL Global

MetaVia

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Bristol-Myers Squibb Company

AMLX

LABU

SBIO

LifeSci Capital analyst Rami Katkhuda has maintained a Buy rating on Amylyx Pharmaceuticals Inc (AMLX) with a price target of $24.00. Katkhuda, a 5-star analyst, has an average return of 30.9% and a success rate of 52.19%. Guggenheim also reiterated a Buy rating with a $30.00 price target.

Tip Ranks

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

iShares US Pharma

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

VanEck Biotech ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

Viridian Therapeutics

Dianthus Therapeutics

LifeSci Capital Remains a Buy on Amylyx Pharmaceuticals Inc (AMLX)

Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation | AMLX Stock News

StockTitan

VG Health

Health Care Select Sector SPDR

Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation | AMLX Stock News

Amylyx Pharmaceuticals is preparing for a pivotal Phase 3 readout for AVEXITIDE, its lead asset for post-bariatric hypoglycemia (PBH), with data expected in Q3 2023. Co-CEO Joshua Cohen highlighted the trial's design to replicate earlier studies showing significant effects on glucose and insulin. If results are positive, the company aims to submit a new drug application for a potential 2027 launch. AVEXITIDE targets the underlying mechanism of PBH, addressing a severe condition with no approved therapies.

Market Beat

Bank of America

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus

Guggenheim analyst Seamus Fernandez has reiterated a Buy rating on Amylyx Pharmaceuticals Inc (AMLX) with a price target of $30.00. Fernandez, who focuses on the Healthcare sector, has an average return of 25.0% and a 61.33% success rate on his stock recommendations. Additionally, LifeSci Capital also assigned a Buy rating to AMLX with a price target of $24.00 in a report released on May 9.

MBX Biosciences

Rhythm Pharma

Bristol Myers Squibb

Amylyx Pharmaceuticals Inc (AMLX) Receives a Buy from Guggenheim

ARKG

Amylyx Pharmaceuticals held its Q1 earnings call, highlighting progress on its avexitide program and the full enrollment of the LUCIDITY trial, with results expected in Q3 2026. The company is preparing for a potential 2027 launch, supported by a cash runway into 2028. However, rising expenses and a decline in cash balance raise execution stakes. Management emphasized the importance of the LUCIDITY trial results as a key risk factor, while also advancing other pipeline programs. Overall, the tone was cautiously optimistic about future developments.

iShares Global Healthcare

Ark Genomic Revolution ETF

Amylyx Pharmaceuticals Charts Path to 2026 Trial Data

SRTS

In Friday's pre-market session, Traws Pharma (NASDAQ:TRAW) shares surged 37% to $2.33, while Amylyx Pharmaceuticals (NASDAQ:AMLX) rose 18.42% to $18.0. Other gainers included Celldex Therapeutics (NASDAQ:CLDX) up 12.54% to $37.5, and InMed Pharmaceuticals (NASDAQ:INM) up 12% to $0.78. Conversely, Sensus Healthcare (NASDAQ:SRTS) fell 25.1% to $3.08, Absci (NASDAQ:ABSI) dropped 19.66% to $4.62, and Amphastar Pharma (NASDAQ:AMPH) decreased 15.65% to $20.27. Most companies reported Q1 earnings yesterday.

benzinga_article

InMed Pharmaceuticals

Sensus Healthcare

Amphastar Pharma

Celldex Therap

Traws Pharma

Absci

Invesco Nasdaq Biotechnology ETF

Progyny

Artiva Biotherapeutics

Capricor Therap

Organogenesis

Artivion

12 Health Care Stocks Moving In Friday's Pre-Market Session

Amylyx Pharmaceuticals (NASDAQ:AMLX) reported a quarterly EPS of ($0.37), missing estimates by $0.03. The company has $279.8 million in cash, funding operations into 2028. Key developments include the LUCIDITY trial and a U.S. expanded access program. Analysts have set new price targets, with a consensus rating of "Moderate Buy" and a target of $23.00. Institutional investors hold 95.84% of the stock, indicating strong interest in the company.

Amylyx Pharmaceuticals (NASDAQ:AMLX) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Rami Katkhuda from LifeSci Capital reiterated a Buy rating on Amylyx Pharmaceuticals with a $24 price target, citing strong financials and progress in avexitide's late-stage development for post-bariatric hypoglycemia. The company has $279.8M in cash, sufficient to fund operations into 2028, reducing financing risks. The pivotal Phase III LUCIDITY trial is expected to drive value, with a potential 2027 launch. Katkhuda has a 31.9% average return and a 54.36% success rate on his stock recommendations.

Disc Medicine

Buy Rating Reiterated on Amylyx as Avexitide Progress and Cash Runway Support Upside vs. Unchanged $24 Price Target

Amylyx Pharmaceuticals highlighted progress in its Q1 2026 earnings call, focusing on the Phase 3 LUCIDITY trial for avexitide in post-bariatric hypoglycemia (PBH). The trial is nearing top-line results, with the last participant dosed in March. The company has launched an expanded access program for PBH patients and is preparing for a potential 2027 commercial launch. Management emphasized the urgency of NDA readiness and plans for a PBH awareness campaign, estimating around 160,000 individuals affected in the U.S.

Amylyx Pharmaceuticals Q1 Earnings Call Highlights

Amylyx Pharmaceuticals(AMLX.US)

LifeSci Capital Remains a Buy on Amylyx Pharmaceuticals Inc (AMLX)

Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation | AMLX Stock News

Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus

Amylyx Pharmaceuticals Inc (AMLX) Receives a Buy from Guggenheim

Amylyx Pharmaceuticals Charts Path to 2026 Trial Data

12 Health Care Stocks Moving In Friday's Pre-Market Session

Amylyx Pharmaceuticals (NASDAQ:AMLX) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Buy Rating Reiterated on Amylyx as Avexitide Progress and Cash Runway Support Upside vs. Unchanged $24 Price Target

Amylyx Pharmaceuticals Q1 Earnings Call Highlights